Literature DB >> 33925355

Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models.

Alessio Gerussi1,2, Ambra Natalini3, Fabrizio Antonangeli3, Clara Mancuso1,2, Elisa Agostinetto4,5,6, Donatella Barisani1,2, Francesca Di Rosa3, Raul Andrade7, Pietro Invernizzi1,2.   

Abstract

Drug-induced liver injury (DILI) is a challenging clinical event in medicine, particularly because of its ability to present with a variety of phenotypes including that of autoimmune hepatitis or other immune mediated liver injuries. Limited diagnostic and therapeutic tools are available, mostly because its pathogenesis has remained poorly understood for decades. The recent scientific and technological advancements in genomics and immunology are paving the way for a better understanding of the molecular aspects of DILI. This review provides an updated overview of the genetic predisposition and immunological mechanisms behind the pathogenesis of DILI and presents the state-of-the-art experimental models to study DILI at the pre-clinical level.

Entities:  

Keywords:  autoimmune hepatitis; autoimmunity; drug-induced liver injury; genetics; inflammation

Year:  2021        PMID: 33925355     DOI: 10.3390/ijms22094557

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  149 in total

1.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

Authors:  Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

2.  Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury.

Authors:  Yoh Zen; Matthew M Yeh
Journal:  Mod Pathol       Date:  2018-02-05       Impact factor: 7.842

3.  Multiparametric assay using HepaRG cells for predicting drug-induced liver injury.

Authors:  Takafumi Tomida; Hayao Okamura; Masahiro Satsukawa; Tsuyoshi Yokoi; Yoshihiro Konno
Journal:  Toxicol Lett       Date:  2015-04-28       Impact factor: 4.372

4.  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Authors:  Wei Ding; Betsy R LaPlant; Timothy G Call; Sameer A Parikh; Jose F Leis; Rong He; Tait D Shanafelt; Sutapa Sinha; Jennifer Le-Rademacher; Andrew L Feldman; Thomas M Habermann; Thomas E Witzig; Gregory A Wiseman; Yi Lin; Erik Asmus; Grzegorz S Nowakowski; Michael J Conte; Deborah A Bowen; Casey N Aitken; Daniel L Van Dyke; Patricia T Greipp; Xin Liu; Xiaosheng Wu; Henan Zhang; Charla R Secreto; Shulan Tian; Esteban Braggio; Linda E Wellik; Ivana Micallef; David S Viswanatha; Huihuang Yan; Asher A Chanan-Khan; Neil E Kay; Haidong Dong; Stephen M Ansell
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

5.  Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury.

Authors:  Seung-Hyun Kim; Katy Saide; John Farrell; Lee Faulkner; Arun Tailor; Monday Ogese; Ann K Daly; Munir Pirmohamed; B Kevin Park; Dean J Naisbitt
Journal:  Hepatology       Date:  2015-07-23       Impact factor: 17.425

6.  Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing.

Authors:  Rui M Tostões; Sofia B Leite; Margarida Serra; Janne Jensen; Petter Björquist; Manuel J T Carrondo; Catarina Brito; Paula M Alves
Journal:  Hepatology       Date:  2012-04       Impact factor: 17.425

7.  Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways.

Authors:  M Laan; Z H Cui; H Hoshino; J Lötvall; M Sjöstrand; D C Gruenert; B E Skoogh; A Lindén
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

8.  Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific.

Authors:  Jun Wu; Zhongji Meng; Min Jiang; Ejuan Zhang; Martin Trippler; Ruth Broering; Agnes Bucchi; Frank Krux; Ulf Dittmer; Dongliang Yang; Michael Roggendorf; Guido Gerken; Mengji Lu; Joerg F Schlaak
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

9.  Modular bioreactor for primary human hepatocyte culture: medium flow stimulates expression and activity of detoxification genes.

Authors:  Bruna Vinci; Cédric Duret; Sylvie Klieber; Sabine Gerbal-Chaloin; Antonio Sa-Cunha; Sylvain Laporte; Bertrand Suc; Patrick Maurel; Arti Ahluwalia; Martine Daujat-Chavanieu
Journal:  Biotechnol J       Date:  2011-01-21       Impact factor: 4.677

10.  A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury.

Authors:  Elizabeth T Cirulli; Paola Nicoletti; Karen Abramson; Raul J Andrade; Einar S Bjornsson; Naga Chalasani; Robert J Fontana; Pär Hallberg; Yi Ju Li; M Isabel Lucena; Nanye Long; Mariam Molokhia; Matthew R Nelson; Joseph A Odin; Munir Pirmohamed; Thorunn Rafnar; Jose Serrano; Kári Stefánsson; Andrew Stolz; Ann K Daly; Guruprasad P Aithal; Paul B Watkins
Journal:  Gastroenterology       Date:  2019-01-18       Impact factor: 22.682

View more
  6 in total

Review 1.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

2.  Acute Hepatitis with Positive Autoantibodies: A Case of Natalizumab-Induced Early-Onset Liver Injury.

Authors:  Marlone Cunha-Silva; Priscilla Brito Sena de Moraes; Pedro Rodrigues de Carvalho; Larissa Bastos Eloy da Costa; Guilherme Rossi Assis-Mendonça; Cristina Alba Lalli; Gisele Conte Alves Fernandes; Fernanda Bocchi Monteiro; Gustavo Manginelli Lamas; Alfredo Damasceno; Daniel Ferraz de Campos Mazo; Tiago Sevá-Pereira
Journal:  Am J Case Rep       Date:  2022-06-29

Review 3.  Challenges and Future of Drug-Induced Liver Injury Research-Laboratory Tests.

Authors:  Sabine Weber; Alexander L Gerbes
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

Review 4.  Animal Models for Autoimmune Hepatitis: Are Current Models Good Enough?

Authors:  Urs Christen; Edith Hintermann
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

5.  Differences in clinical characteristics among 726 patients with Chinese herbal medicine- or Western medicine-induced liver injury.

Authors:  Kangan Tan; Wanna Yang; Lili Pang; Fengqin Hou
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

6.  Osimertinib-related liver injury with successful osimertinib rechallenge: A case report.

Authors:  Yuan-Ling Cheng; Wei-Kuo Chang; Hao Yen; Yi-Jen Peng; Wei-Chou Chang; Ping-Ying Chang
Journal:  Thorac Cancer       Date:  2022-07-06       Impact factor: 3.223

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.